We at the JDCA believe it is imperative to prioritize cure research that can achieve near-term solutions.  There are only a small number of organizations in the world which have T1D Practical Cure research in human clinical trials.  During Diabetes Awareness month in 2014 we kicked off an interview series with the researchers working on these projects. 

These interviews explain the projects in the researchers’ own words, including a basic description of their scientific approach, projected milestones, and when we can expect results.

Diabecell

November 17, 2014

Diabecell is an islet cell transplantation approach that utilizes encapsulated, insulin-producing porcine islet cells. The project completed phase 1 trials to inconclusive results and is expected to start phase 2/3 early next year.  Click here to the interview with Dr. Andrea Grant, CEO of Diatranz Otsuka Limited.


BCG

November 13, 2014

BCG, a project led by Dr. Denise Faustman, Director of the Massachusetts General Hospital Immunology Laboratory, is a tuberculosis drug that Faustman believes will stop the autoimmune attack and allow residual beta cells to replicate.  Phase I trials were completed a few years ago with inconclusive results.  Phase II trials are currently underway.  We look forward to seeing the results.  Click here to read the interview with Dr. Denise Faustman. 


BIOHUB

November 21, 2014

The BioHub is a multi-platform initiative led by Dr. Camillo Ricordi which is working toward a bio-engineered “mini organ” designed to mimic normal pancreas activities.  They are now beginning Phase I human trial testing of one aspect of the BioHub, a biodegradable scaffold.  Click here to read the interview with Dr. Camillo Ricordi.


Beta 02

November 10, 2014

BO2 is entering human trials in Sweden with a unique encapsulation approach that prioritizes oxygen delivery to the cells.  First results for their phase I trial are expected in early 2015.  Click here to read the interview with Dr. Dan Gelvan, Ph.D., Managing Director, Life Sciences, Aurum Ventures MKI.


Bionic Pancreas 

December 10, 2014

The Bionic Pancreas is a bi-hormonal closed-loop pump and continuous glucose monitoring device.  The system delivers insulin and glucagon, and measures and adapts to each individual in real time. It is currently in human clinical trials. Click here to read the interview with Dr. Ed Damiano.


CLYCOPSPORINE LANSOPRAZOLE

December 18, 2014

The Cyclosporine Lansoprazole trial aims to regenerate pancreatic beta cells as well as lower the body’s autoimmune attack on these newly formed beta cells. We look forward to seeing the results as they start trials in 2015. Click here to read the interview with Dr. Claresa Levetan, CEO of Perle Biosciences.

 


Stem Cell Educator 

November 25, 2014

The Stem Cell Educator is an immune system retraining method.  Over several hours, a patient’s blood continuously passes through a machine which exposes blood cells involved in the autoimmune attack to cord blood stem cells, which ‘remind’ the immune system how to act properly.  Phase II trials have started and we look forward to the results which will reveal how frequently the procedure must be performed.  Click here to read the interview with Dr. Yong Zhao.